{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:35:22Z","timestamp":1771868122685,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102280"],"award-info":[{"award-number":["82102280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270185"],"award-info":[{"award-number":["82270185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202398"],"award-info":[{"award-number":["82202398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Research Project of Hunan Provincial Health Commission","award":["W20242008"],"award-info":[{"award-number":["W20242008"]}]},{"name":"Health Research Project of Hunan Provincial Health Commission","award":["W20243126"],"award-info":[{"award-number":["W20243126"]}]},{"name":"the Science and Technology Innovation Program of Hunan Province","award":["2022RC3077"],"award-info":[{"award-number":["2022RC3077"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03965-x","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:29Z","timestamp":1740055769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["IgA vasculitis induced by tumor necrosis factor-\u03b1 antagonists: clinical features, diagnosis and management"],"prefix":"10.1007","volume":"317","author":[{"given":"Lu","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"3965_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. 2019\/03\/31","journal-title":"Ann Rheum Dis"},{"key":"3965_CR2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339. 2016\/12\/13","journal-title":"Ann Rheum Dis"},{"key":"3965_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. 2022\/11\/11","journal-title":"Ann Rheum Dis"},{"key":"3965_CR4","doi-asserted-by":"publisher","first-page":"103332","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, Pallavicini FB, Mauric E et al (2023) Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev 22:103332 2023\/04\/17. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332","journal-title":"Autoimmun Rev"},{"key":"3965_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15097","volume":"49","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Sharratt CL, Thomas T et al (2019) Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 49:664\u2013680 2019\/02\/09. https:\/\/doi.org\/10.1111\/apt.15097","journal-title":"Aliment Pharmacol Ther"},{"key":"3965_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M (2013) Biologics-induced autoimmune diseases. Curr Opin Rheumatol 25:56\u201364 2012\/11\/02. https:\/\/doi.org\/10.1097\/BOR.0b013e32835b1366","journal-title":"Curr Opin Rheumatol"},{"key":"3965_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","volume":"73","author":"B Saint Marcoux","year":"2006","unstructured":"Saint Marcoux B, De Bandt M (2006) Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73:710\u2013713 2006\/11\/28. https:\/\/doi.org\/10.1016\/j.jbspin.2006.02.010","journal-title":"Joint Bone Spine"},{"key":"3965_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","volume":"10","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Cuadrado MJ et al (2008) Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 10:442\u2013448 2008\/11\/15. https:\/\/doi.org\/10.1007\/s11926-008-0072-z","journal-title":"Curr Rheumatol Rep"},{"key":"3965_CR9","first-page":"S106","volume":"24","author":"TN Duffy","year":"2006","unstructured":"Duffy TN, Genta M, Moll S et al (2006) Henoch Sch\u00f6nlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 24:S106 2006\/07\/25","journal-title":"Clin Exp Rheumatol"},{"key":"3965_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/15563650.2024.2348108","volume":"62","author":"M Joseph","year":"2024","unstructured":"Joseph M, Amin K, Siddens C et al (2024) Pulmonary edema after naloxone administration for opioid reversal: a systematic review of case reports and causality assessment using the Naranjo scale. Clin Toxicol (Phila) 62:334\u2013342. 2024\/06\/12","journal-title":"Clin Toxicol (Phila)"},{"key":"3965_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM et al (2010) EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 69:798\u2013806. 2010\/04\/24","journal-title":"Ann Rheum Dis"},{"key":"3965_CR12","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.mayocp.2019.04.034","volume":"94","author":"M Villatoro-Villar","year":"2019","unstructured":"Villatoro-Villar M, Crowson CS, Warrington KJ et al (2019) Clinical characteristics of biopsy-proven IgA vasculitis in children and adults: a retrospective cohort study. Mayo Clin Proc 94:1769\u20131780 2019\/09\/06. https:\/\/doi.org\/10.1016\/j.mayocp.2019.04.034","journal-title":"Mayo Clin Proc"},{"key":"3965_CR13","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/art.40178","volume":"69","author":"A Audemard-Verger","year":"2017","unstructured":"Audemard-Verger A, Terrier B, Dechartres A et al (2017) Characteristics and management of IgA Vasculitis (Henoch-Sch\u00f6nlein) in adults: data from 260 patients included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 69:1862\u20131870. 2017\/06\/13","journal-title":"Arthritis Rheumatol"},{"key":"3965_CR14","doi-asserted-by":"publisher","unstructured":"Alsulami S, Alotaibi RM, Alotaibi FF et al (2022) IgA Vasculitis With Adalimumab Therapy for Hidradenitis Suppurativa: A Case Report and Review of Literature. Cureus.; 14: e30122. 2022\/11\/17. https:\/\/doi.org\/10.7759\/cureus.30122","DOI":"10.7759\/cureus.30122"},{"key":"3965_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4292\/wjgpt.v1.i5.119","volume":"1","author":"FZ Rahman","year":"2010","unstructured":"Rahman FZ, Takhar GK, Roy O et al (2010) Henoch-Sch\u00f6nlein purpura complicating adalimumab therapy for Crohn\u2019s disease. World J Gastrointest Pharmacol Ther 1:119\u2013122 2011\/05\/18. https:\/\/doi.org\/10.4292\/wjgpt.v1.i5.119","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"3965_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ecco-jcc\/jjz164","volume":"14","author":"M Condamina","year":"2020","unstructured":"Condamina M, Diaz E, Jamart C et al (2020) Severe attack of Henoch-Sch\u00f6nlein Purpura with neurological involvement during Adalimumab Treatment for Crohn\u2019s Disease. J Crohns Colitis 14:538\u2013542. 2019\/10\/08","journal-title":"J Crohns Colitis"},{"key":"3965_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/RHU.0b013e31819bca9e","volume":"15","author":"S Nobile","year":"2009","unstructured":"Nobile S, Catassi C, Felici L (2009) Herpes zoster infection followed by Henoch-Sch\u00f6nlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 15:101. https:\/\/doi.org\/10.1097\/RHU.0b013e31819bca9e. 2009\/03\/07","journal-title":"J Clin Rheumatol"},{"key":"3965_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.rhu.0000239901.34561.5e","volume":"12","author":"A Lee","year":"2006","unstructured":"Lee A, Kasama R, Evangelisto A et al (2006) Henoch-Sch\u00f6nlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 12:249\u2013251 2006\/10\/07. https:\/\/doi.org\/10.1097\/01.rhu.0000239901.34561.5e","journal-title":"J Clin Rheumatol"},{"key":"3965_CR19","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.3748\/wjg.v21.i19.6082","volume":"21","author":"Y Song","year":"2015","unstructured":"Song Y, Shi YH, He C et al (2015) Severe Henoch-Sch\u00f6nlein purpura with infliximab for ulcerative colitis. World J Gastroenterol 21:6082\u20136087 2015\/05\/29. https:\/\/doi.org\/10.3748\/wjg.v21.i19.6082","journal-title":"World J Gastroenterol"},{"key":"3965_CR20","first-page":"E20","volume":"99","author":"C Laresche","year":"2017","unstructured":"Laresche C, Locatelli F, Biver-Dalle C et al (2017) Severe Henoch-Sch\u00f6nlein purpura complicating infliximab therapy for ulcerative colitis. Cutis 99:E20\u2013e22 2017\/02\/17","journal-title":"Cutis"},{"key":"3965_CR21","doi-asserted-by":"publisher","unstructured":"LaConti JJ, Donet JA, Cho-Vega JH et al (2016) Henoch-Sch\u00f6nlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature. Case Rep Rheumatol.; 2016: 2812980. 2016\/08\/17. https:\/\/doi.org\/10.1155\/2016\/2812980","DOI":"10.1155\/2016\/2812980"},{"key":"3965_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/RHU.0b013e3182863027","volume":"19","author":"AS Rolle","year":"2013","unstructured":"Rolle AS, Zimmermann B, Poon SH (2013) Etanercept-induced Henoch-Sch\u00f6nlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol 19:90\u201393 2013\/02\/01. https:\/\/doi.org\/10.1097\/RHU.0b013e3182863027","journal-title":"J Clin Rheumatol"},{"key":"3965_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1684\/ejd.2010.0977","volume":"20","author":"A Asahina","year":"2010","unstructured":"Asahina A, Ohshima N, Nakayama H et al (2010) Henoch-Sch\u00f6nlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol 20:521\u2013522. 2010\/04\/24","journal-title":"Eur J Dermatol"},{"key":"3965_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.crohns.2012.02.019","volume":"6","author":"I Marques","year":"2012","unstructured":"Marques I, Lagos A, Reis J et al (2012) Reversible Henoch-Sch\u00f6nlein purpura complicating adalimumab therapy. J Crohns Colitis 6:796\u2013799 2012\/03\/27. https:\/\/doi.org\/10.1016\/j.crohns.2012.02.019","journal-title":"J Crohns Colitis"},{"key":"3965_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.17235\/reed.2022.9414\/2022","volume":"115","author":"C Sequeira","year":"2023","unstructured":"Sequeira C, Santos I, Lopes S et al (2023) Henoch-Sch\u00f6nlein purpura masquerading as Crohn\u2019s disease flare. Rev Esp Enferm Dig 115:581 2022\/12\/24. https:\/\/doi.org\/10.17235\/reed.2022.9414\/2022","journal-title":"Rev Esp Enferm Dig"},{"key":"3965_CR26","doi-asserted-by":"publisher","first-page":"e1074","DOI":"10.1097\/MEG.0000000000002046","volume":"33","author":"X Li","year":"2021","unstructured":"Li X, Wang Y, Ge T et al (2021) Henoch-Sch\u00f6nlein purpura associated with infliximab therapy for pediatric Crohn\u2019s disease. Eur J Gastroenterol Hepatol 33:e1074\u2013e1075. 2021\/08\/26","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3965_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1684\/ejd.2017.2979","volume":"27","author":"RR Pinheiro","year":"2017","unstructured":"Pinheiro RR, Lencastre A (2017) Henoch-Sch\u00f6nlein purpura during anti-TNF\u03b1 therapy: a fortuitous event or an indication to stop therapy? Eur J Dermatol 27:304\u2013305. 2017\/05\/05","journal-title":"Eur J Dermatol"},{"key":"3965_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12882-023-03439-0","volume":"24","author":"A Przygocka","year":"2023","unstructured":"Przygocka A, Berti GM, Campus A et al (2023) Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement. BMC Nephrol 24:381 2023\/12\/21. https:\/\/doi.org\/10.1186\/s12882-023-03439-0","journal-title":"BMC Nephrol"},{"key":"3965_CR29","first-page":"110","volume":"87","author":"N Urganci","year":"2022","unstructured":"Urganci N, Sakar M, Yalc\u00edn O et al (2022) Henoch-Sch\u00f6nlein purpura induced by infliximab for Crohn\u2019s disease: a case report and literature review. Rev Gastroenterol Mex (Engl Ed) 87:110\u2013112. 2021\/11\/15","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"3965_CR30","unstructured":"Tingting Shen (2021) A case report of adalimumab induced anaphylactoid purpura in the treatment of articular psoriasis and literature review. Anhui Medical University"},{"key":"3965_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/pde.14818","volume":"38","author":"AP Sheth","year":"2021","unstructured":"Sheth AP, Vivar KL, Wagner AM et al (2021) Henoch Schonlein purpura in pediatric patients with inflammatory bowel disease: a case series. Pediatr Dermatol 38:1389\u20131392 2021\/09\/26. https:\/\/doi.org\/10.1111\/pde.14818","journal-title":"Pediatr Dermatol"},{"key":"3965_CR32","doi-asserted-by":"publisher","unstructured":"Flanagan E, Chaivannacoopt K, Kanaan Z et al (2022) Infliximab-induced IgA vasculitis. J Gastroenterol Hepatol 37(137\u2013138). https:\/\/doi.org\/10.1111\/jgh.15953. Conference Abstract","DOI":"10.1111\/jgh.15953"},{"key":"3965_CR33","doi-asserted-by":"publisher","unstructured":"Keeley M, Cloney D, Kammeraad C (2019) A case of henoch-schonlein purpura during infliximab treatment for ulcerative colitis. Am J Gastroenterol 114(S12). https:\/\/doi.org\/10.14309\/01.ajg.0000613152.33564.c1. Conference Abstract","DOI":"10.14309\/01.ajg.0000613152.33564.c1"},{"key":"3965_CR34","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.11405\/NISSHOSHI.112.1852","volume":"112","author":"J Nishikawa","year":"2015","unstructured":"Nishikawa J, Hosokawa A, Akashi M et al (2015) IgA vasculitis associated with anti-TNF-\u03b1 inhibitors in a patient with Crohn\u2019s disease. J Japanese Soc Gastroenterol 112:1852\u20131857 Article. https:\/\/doi.org\/10.11405\/NISSHOSHI.112.1852","journal-title":"J Japanese Soc Gastroenterol"},{"key":"3965_CR35","doi-asserted-by":"publisher","unstructured":"Stallard L (2021) P Church RECURRENT HENOCH-SCHONLEIN PURPURA FOLLOWING TREATMENT WITH ADALIMUMAB. J Can Association Gastroenterol 4 https:\/\/doi.org\/10.1093\/jcag\/gwab002.151 Conference Abstract.","DOI":"10.1093\/jcag\/gwab002.151"},{"key":"3965_CR36","doi-asserted-by":"publisher","unstructured":"Vangimalla S, Mirza MU, Choden T et al (2019) A rare case of IGA vasculitis secondary to infliximab use in Crohn\u2019s disease. Am J Gastroenterol 114(S1154\u2013S1155). https:\/\/doi.org\/10.14309\/01.ajg.0000597792.84009.7b. Conference Abstract","DOI":"10.14309\/01.ajg.0000597792.84009.7b"},{"key":"3965_CR37","doi-asserted-by":"publisher","unstructured":"Varadarajan N, Prakash P, Reich J et al (2012) Henoch-sch\u00f6nlein purpura occurring 5 years after initiation of adalimumab. Inflamm Bowel Dis 18(S17). https:\/\/doi.org\/10.1002\/ibd.23058. Conference Abstract","DOI":"10.1002\/ibd.23058"},{"key":"3965_CR38","doi-asserted-by":"publisher","unstructured":"Voth E, Olson E, Raffals LE (2019) A case of IgA vasculitis in Crohn\u2019s disease and recurrent clostridioides difficile infection. American Journal of Gastroenterology.; 114: S1175. Conference Abstract. https:\/\/doi.org\/10.14309\/01.ajg.0000597972.33667.cd","DOI":"10.14309\/01.ajg.0000597972.33667.cd"},{"key":"3965_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2169\/internalmedicine.9059-21","volume":"62","author":"M Fukuda","year":"2023","unstructured":"Fukuda M, Sawa N, Ikuma D et al (2023) Endothelial damage-dominant Nephritis related to IgA Vasculitis after 11 years\u2019 use of Infliximab for Rheumatoid Arthritis. Intern Med 62:81\u201385. 2022\/06\/02","journal-title":"Intern Med"},{"key":"3965_CR40","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.2022\/11\/30","volume":"110","author":"PA Young","year":"2022","unstructured":"Young PA, Su MW, Inkeles MS et al (2022) IgA Vasculitis in the setting of Biologic Therapy for Psoriasis and recurrent cutaneous methicillin-resistant Staphylococcus aureus colonization. Cutis 110:E4\u2013e. https:\/\/doi.org\/10.2022\/11\/30","journal-title":"Cutis"},{"key":"3965_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12328-020-01280-8","volume":"14","author":"J Urushikubo","year":"2021","unstructured":"Urushikubo J, Yanai S, Nakamura S et al (2021) IgA vasculitis in a patient with ulcerative colitis under infliximab: drug-induced or genetic? Clin J Gastroenterol 14:198\u2013203 2020\/11\/04. https:\/\/doi.org\/10.1007\/s12328-020-01280-8","journal-title":"Clin J Gastroenterol"},{"key":"3965_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.20452\/pamw.4435","volume":"129","author":"A Hokama","year":"2019","unstructured":"Hokama A, Sonosaki T, Zamami R et al (2019) Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor-\u03b1 inhibitor. Pol Arch Intern Med 129:283\u2013284 2019\/02\/09. https:\/\/doi.org\/10.20452\/pamw.4435","journal-title":"Pol Arch Intern Med"},{"key":"3965_CR43","doi-asserted-by":"publisher","first-page":"e943912","DOI":"10.12659\/msm.943912","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV (2024) A review of IgA Vasculitis (Henoch-Sch\u00f6nlein Purpura) Past, Present, and Future. Med Sci Monit 30:e943912 2024\/01\/28. https:\/\/doi.org\/10.12659\/msm.943912","journal-title":"Med Sci Monit"},{"key":"3965_CR44","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.1780330812","volume":"33","author":"JF Fries","year":"1990","unstructured":"Fries JF, Hunder GG, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary Arthritis Rheum 33:1135\u20131136. 1990\/08\/01","journal-title":"Summary Arthritis Rheum"},{"key":"3965_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13052-016-0267-2","volume":"42","author":"L Da Dalt","year":"2016","unstructured":"Da Dalt L, Zerbinati C, Strafella MS et al (2016) Henoch-Sch\u00f6nlein purpura and drug and vaccine use in childhood: a case-control study. Ital J Pediatr 42:60. 2016\/06\/19","journal-title":"Ital J Pediatr"},{"key":"3965_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fped.2019.00257","volume":"7","author":"L Oni","year":"2019","unstructured":"Oni L, Sampath S (2019) Childhood IgA vasculitis (Henoch Schonlein Purpura)-Advances and knowledge gaps. Front Pediatr 7:257. https:\/\/doi.org\/10.3389\/fped.2019.00257. 2019\/07\/19","journal-title":"Front Pediatr"},{"key":"3965_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.semarthrit.2005.08.007","volume":"35","author":"S Trapani","year":"2005","unstructured":"Trapani S, Micheli A, Grisolia F et al (2005) Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 35:143\u2013153. 2005\/12\/06","journal-title":"Semin Arthritis Rheum"},{"key":"3965_CR48","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen S, Marks SD, Brogan P et al (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58:1607\u20131616. 2019\/03\/18","journal-title":"Rheumatology (Oxford)"},{"key":"3965_CR49","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaad.2020.03.104","volume":"82","author":"WR Heymann","year":"2020","unstructured":"Heymann WR (2020) The renal reality of adult Henoch-Sch\u00f6nlein purpura. J Am Acad Dermatol 82:1303\u20131304 2020\/04\/13. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.104","journal-title":"J Am Acad Dermatol"},{"key":"3965_CR50","doi-asserted-by":"publisher","first-page":"102707","DOI":"10.1016\/j.autrev.2020.102707","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Tisseyre M, Garon-Czmil J et al (2021) Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun Rev 20:102707. 2020\/11\/17","journal-title":"Autoimmun Rev"},{"key":"3965_CR51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10157-019-01726-5","volume":"23","author":"EK \u00c7ak\u0131c\u0131","year":"2019","unstructured":"\u00c7ak\u0131c\u0131 EK, G\u00fcr G, Yaz\u0131l\u0131ta\u015f F et al (2019) A retrospective analysis of children with Henoch-Schonlein purpura and re-evaluation of renal pathologies using Oxford classification. Clin Exp Nephrol 23:939\u2013947. 2019\/03\/22","journal-title":"Clin Exp Nephrol"},{"key":"3965_CR52","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1007\/s00467-023-06023-8","volume":"38","author":"HK Stone","year":"2023","unstructured":"Stone HK, Mitsnefes M, Dickinson K et al (2023) Clinical course and management of children with IgA vasculitis with nephritis. Pediatr Nephrol 38:3721\u20133733 2023\/06\/15. https:\/\/doi.org\/10.1007\/s00467-023-06023-8","journal-title":"Pediatr Nephrol"},{"key":"3965_CR53","first-page":"1955","volume":"31","author":"N Mohan","year":"2004","unstructured":"Mohan N, Edwards ET, Cupps TR et al (2004) Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31:1955\u20131958 2004\/10\/07","journal-title":"J Rheumatol"},{"key":"3965_CR54","first-page":"1885","volume":"31","author":"L Guillevin","year":"2004","unstructured":"Guillevin L, Mouthon L (2004) Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 31:1885\u20131887 2004\/10\/07","journal-title":"J Rheumatol"},{"key":"3965_CR55","doi-asserted-by":"publisher","unstructured":"Grau RG (2015) Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects. Curr Rheumatol Rep.; 17: 71. 2015\/10\/28. https:\/\/doi.org\/10.1007\/s11926-015-0545-9","DOI":"10.1007\/s11926-015-0545-9"},{"key":"3965_CR56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2015\/06\/21","volume":"10","author":"JJ Hogan","year":"2015","unstructured":"Hogan JJ, Markowitz GS, Radhakrishnan J (2015) Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol 10:1300. 1310.2015\/06\/21","journal-title":"Clin J Am Soc Nephrol"},{"key":"3965_CR57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","volume":"255","author":"F D\u2019Auria","year":"2004","unstructured":"D\u2019Auria F, Rovere-Querini P, Giazzon M et al (2004) Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 255:409\u2013418 2004\/02\/12. https:\/\/doi.org\/10.1111\/j.1365-2796.2003.01298.x","journal-title":"J Intern Med"},{"key":"3965_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"M Her","year":"2016","unstructured":"Her M, Kavanaugh A (2016) Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137:19\u201327 2016\/01\/16. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.023","journal-title":"J Allergy Clin Immunol"},{"key":"3965_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11926-016-0588-6","volume":"18","author":"LA Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez LA (2016) Biological Therapy-Induced systemic vasculitis. Curr Rheumatol Rep 18:39. 2016\/05\/12","journal-title":"Curr Rheumatol Rep"},{"key":"3965_CR60","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","volume":"61","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Abitbol V, El Karoui K et al (2022) IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-\u03b1 blockers. Rheumatology (Oxford) 61:1957\u20131965 2021\/08\/25. https:\/\/doi.org\/10.1093\/rheumatology\/keab662","journal-title":"Rheumatology (Oxford)"},{"key":"3965_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ndt\/gfaa378","volume":"37","author":"N Joher","year":"2022","unstructured":"Joher N, Gosset C, Guerrot D et al (2022) Immunoglobulin a nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transpl 37:531\u2013539. 2021\/01\/09","journal-title":"Nephrol Dial Transpl"},{"key":"3965_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ekir.2020.03.012","volume":"5","author":"N Champtiaux","year":"2020","unstructured":"Champtiaux N, Liot\u00e9 F, El Karoui K et al (2020) Spondyloarthritis-Associated IgA Nephropathy. Kidney Int Rep 5:813\u2013820 2020\/06\/11. https:\/\/doi.org\/10.1016\/j.ekir.2020.03.012","journal-title":"Kidney Int Rep"},{"key":"3965_CR63","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10067-006-0422-z","volume":"26","author":"GT Sakellariou","year":"2007","unstructured":"Sakellariou GT, Vounotrypidis P, Berberidis C (2007) Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 26:1132\u20131133 2006\/08\/23. https:\/\/doi.org\/10.1007\/s10067-006-0422-z","journal-title":"Clin Rheumatol"},{"key":"3965_CR64","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00296-012-2624-9","volume":"33","author":"SH Lee","year":"2013","unstructured":"Lee SH, Lee EJ, Chung SW et al (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33:1689\u20131692 2012\/12\/28. https:\/\/doi.org\/10.1007\/s00296-012-2624-9","journal-title":"Rheumatol Int"},{"key":"3965_CR65","doi-asserted-by":"publisher","unstructured":"Sugino H, Kawahara H, Yamamoto K et al (2024) Pyoderma gangrenosum-like lesions in the setting of IgA cutaneous vasculitis: Favourable response to adalimumab. Skin Health Dis.; 4: e347. 2024\/04\/05. https:\/\/doi.org\/10.1002\/ski2.347","DOI":"10.1002\/ski2.347"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03965-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:39Z","timestamp":1740055779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3965"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03965-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data are all from the public database, which does not involve ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}